Video

Looking Ahead: Unmet Needs for the Treatment of BCC

Author(s):

Nikhil Khushalani, MD

Nikhil Khushalani, MD, comments on upcoming treatment advances he looks forward to for patients with BCC.

Related Videos
Nivolumab plus relatlimab vs nivolumab in previously untreated metastatic or unresectable melanoma (RELATIVITY-047): overall survival and melanoma-specific survival outcomes at 3 years
Long-term follow up for adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma: Final results of the COMBI-AD study
Phase 3 study (PIVOTAL) of neoadjuvant intralesional daromun vs. immediate surgery in fully resectable melanoma with regional skin and/or nodal metastases
Zeynep Eroglu, MD
Zeynep Eroglu, MD
Zeynep Eroglu, MD
Zeynep Eroglu, MD
Daniel Olson, MD
Vishal Patel, MD, FAAD, FACMS, associate professor, Dermatology, George Washington (GW) School of Medicine & Health Sciences
Omid Hamid, MD, professor, medicine, Cedars-Sinai; director, Clinical Research and Immunotherapy, director, Cutaneous Oncology and Melanoma, The Angeles Clinic and Research Institute
Related Content
Recent Advances in the Evolving Treatment Landscape of Melanoma
June 14th 2024

Recent Advances in the Evolving Treatment Landscape of Melanoma

Jeffrey S. Weber, MD, PhD
November 6th 2023

FDA Approval Insights: Adjuvant Nivolumab in Completely Resected Stage IIB/C Melanoma

Sushil Patel, PhD, chief executive officer, Replimune
June 6th 2024

New Data With RP1 Plus Nivolumab in PD-1–Refractory Melanoma Build on Positive Findings

Nikhil I. Khushalani, MD; Martin F. Dietrich, MD, PhD; Jason J. Luke, MD, FACP; Vishal A. Patel, MD, FAAD, FACMS
March 6th 2023

CSCC Experts Discuss Considerations for Determining Resectable Disease and Translating Data Into Practice

Caroline Robert MD, PhD
June 1st 2024

Encorafenib/Binimetinib Induction Before Nivolumab/Ipilimumab Does Not Boost PFS in BRAF V600E/K+ Metastatic Melanoma

Georgina V. Long, MD, MSc, of The University of Sydney
June 1st 2024

Up to 10 Years of Follow-Up Uphold Survival Benefit With Adjuvant Dabrafenib/Trametinib in Stage III Melanoma